Once- versus twice-daily abacavir and lamivudine in African children: the randomised controlled ARROW Trial

समान संसाधन

• Pharmacokinetics and acceptability of once- versus twice-daily lamivudine and abacavir in HIV type-1-infected Ugandan children in the ARROW Trial.
  द्वारा: Musiime, V, और अन्य
  प्रकाशित: (2010)
• Virological response and resistance among HIV-infected children receiving long-term antiretroviral therapy without virological monitoring in Uganda and Zimbabwe: Observational analyses within the randomised ARROW trial
  द्वारा: Szubert, A, और अन्य
  प्रकाशित: (2017)
• Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children.
  द्वारा: Green, H, और अन्य
  प्रकाशित: (2007)
• Virological response and resistance among HIV-infected children receiving long-term antiretroviral therapy without virological monitoring in Uganda and Zimbabwe: Observational analyses within the randomised ARROW trial.
  द्वारा: Alexander J Szubert, और अन्य
  प्रकाशित: (2017-11-01)
• Plasma pharmacokinetics of once- versus twice-daily lamivudine and abacavir: simplification of combination treatment in HIV-1-infected children (PENTA-13).
  द्वारा: Bergshoeff, A, और अन्य
  प्रकाशित: (2005)